Paxlovid led to better outcomes in hospitalized COVID cohort than Veklury or both drugs Hospitalized COVID-19 patients treated with the antiviral drug nirmatrelvir–ritonavir (Paxlovid) are at lower risk for death, intensive care unit (ICU) admission, and need for ventilation than those given a combination of Paxlovid and the antiviral drug remdesivir (Veklury) or Veklury alone, a University of Hong Kong target trial emulation study suggests. CIDRAP

...

Both Veklury and Paxlovid are prescribed for patients with mild or moderate COVID-19 at risk for severe disease, but Paxlovid is not given to many hospitalized patients because of contraindications.

...